0001140361-17-010117.txt : 20170301 0001140361-17-010117.hdr.sgml : 20170301 20170301205611 ACCESSION NUMBER: 0001140361-17-010117 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170223 FILED AS OF DATE: 20170301 DATE AS OF CHANGE: 20170301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hunt Anthony CENTRAL INDEX KEY: 0001606030 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-14656 FILM NUMBER: 17656697 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02452 4 1 doc1.xml FORM 4 X0306 4 2017-02-23 0 0000730272 REPLIGEN CORP RGEN 0001606030 Hunt Anthony C/O REPLIGEN CORPORATION 41 SEYON ST, BLDG 1, STE 100 WALTHAM MA 02453 0 1 0 0 Chief Executive Officer Common Stock 2017-02-23 4 A 0 32488 0.00 A 100830 D Common Stock 2017-03-01 4 F 0 5972 32.0704 D 94858 D Stock Option (Right to Buy) 32.32 2017-02-23 4 A 0 64975 0.00 A 2027-02-23 Common Stock 64975 64975 D Mr. Hunt was awarded 32,488 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The Restricted Stock Units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Payment of tax liability made via forfeiture of 5,972 shares of Common Stock valued at a weighted average price of $32.0704 per share on March 1, 2017. The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. /s/ Jeffrey P. Leduc (Attorney in Fact) 2017-03-01